Keywords
High flow nasal oxygen, high flow nasal therapy, acute type 2 respiratory failure, acute hypercapnic respiratory failure, acute exacerbation of chronic obstructive pulmonary disease
High flow nasal oxygen, high flow nasal therapy, acute type 2 respiratory failure, acute hypercapnic respiratory failure, acute exacerbation of chronic obstructive pulmonary disease
The authors looked into the reviewers' valuable comments and took into consideration their recommended changes to improve the systematic review. Minor changes have been suggested by one of the reviewers. These minor changes include adding citations suggested by the reviewer which can add a broad idea about the topic. These citations were added to the background section of the review. The other change is suggested in the discussion section which has been modified according to the reviewer’s recommendation.
See the authors' detailed response to the review by Ben Messer
See the authors' detailed response to the review by Federico Longhini
Acute type two respiratory failure (AT2RF) is characterised by arterial hypercapnia (PaCO2 >6 kPa or >45 mmHg) and its treatment requires ventilator support in a significant proportion of cases.1 Chronic obstructive pulmonary disease (COPD) is the second-most widespread disease in the UK, with 1,201,685 cases reported in 2013. Acute exacerbations of COPD (AECOPD) account for 100,000 admissions annually in England. Of these, around 20% will present with or develop hypercapnia, an indicator of increased risk of death.2,3 Development of AT2RF in patients with COPD is associated with a significantly increased risk for requiring invasive ventilation and mortality rate,4,5 with mortality rates up to 15% in patients who require admission to the intensive care unit (ICU).
The treatment of AT2RF is aimed at the underlying pathological processes such as fluid overload, bronchospasm and infection along with controlled oxygen therapy, to decrease the work of breathing. Patients often require ventilator support that may be non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV). Current guidelines recommend the use of NIV.1 Current evidence has established the role of NIV in improving arterial oxygenation, hypercapnia, acidosis, mortality and intubation rates.6 However, the NIV failure rate ranges from 15 to 25%, with some evidence stating a failure rate as high as 60%.7–10 The factors leading to NIV failure include non-compliance due to claustrophobia, delirium, sputum retention, reduced communication and skin compromise such as skin necrosis in the nasal bridge.1,10,11
High flow nasal oxygen or insufflation (described as high flow nasal therapy (HFNT) in this manuscript) is novel respiratory support that integrates humidified air with a high flow rate of up to 60 L/minute. Reported benefits from HFNT include consistent fractional inspired oxygen delivery, dead space washout, reduced work of breath, comfort and tolerability, ability to communicate, mucous clearance and NIV-like effects, which makes it a more tolerable method for patients.12–15 In type I ARF with different aetiologies, HFNT has been demonstrated to lead to improved oxygenation, lower rates of endotracheal intubations and lower mortality.16,17
In the last 10 years, evidence has emerged for its increasing use and a role for these modalities in clinical practice for the treatment of AT2RF.15,18 Several observational studies have suggested potential benefits of HFNT for AT2RF as demonstrated by improved gas exchange and acidosis,19,20 and reductions in the respiratory rate and work of breathing.21–23 Individual studies have shown that HFNT improves blood gas levels in AT2RF patients22–25 and is associated with improved comfort.24
Adequate respiratory support through controlled oxygen, reduced work of breathing and CO2 clearance is essential to prevent intubation and invasive ventilation. NIV, despite its frequent use, has limitations and a high failure rate. HFNT might overcome the limitations of NIV and could be used in AT2RF patients as an initial intervention or in patients who do not tolerate NIV. Despite the increase in current literature suggesting benefits from the use of HFNT in AT2RF, current evidence is limited. Other systematic reviews are exploring the use of HFNT for the management of AT2RF post-extubation and after initial stabilization of the patient using a respiratory optimisation method like NIV or LFO.26-28 However, there is no systematic review that focuses on the use of HFNT as an initial management strategy for AT2RF.
The primary objective of this systematic review was to determine whether the use of HFNT for patients with AT2RF improves PaCO2 in comparison to LFO or NIV. Secondary objectives were to examine whether HFNT in patients with AT2RF improves other clinical or patient-centred outcomes and to assess any potential harms.
The systematic review was registered in the PROSPERO database (CRD42019148748, 05/09/2019) and published a priori. We conducted this systematic review according to the PRISMA guidelines (see Reporting guidelines).29,30
Randomized controlled trials, uncontrolled trials and cohort studies were included if they compared the use of HFNT with a flow rate >20 L/minutes versus LFO or NIV. We included studies of adult (≥18 years old) patients with AT2RF (>6 kPa or >45 mmHg) managed as inpatients in an acute care setting (emergency department, respiratory ward or critical care units). We excluded reports that described the use of HFNT in peri-operative settings, drug overdose, or ventilator weaning.
The primary outcome for this review was the change in PaCO2 post-intervention (measured at time points reported by authors). The secondary outcomes were: respiratory parameters including pH, the partial arterial pressure of oxygen (PaO2), dyspnoea score, tidal volume and minute volume; mucous clearance (before, during or after HFNT application); the level of consciousness; patient comfort; intubation rate; length of stay in hospital; mortality; post-discharge COPD exacerbation rate and readmission rate secondary to AECOPD.
We searched the electronic databases MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials from January 1999 to January 2021. The databases search was conducted on 15/01/2021. Language restrictions were not applied. In addition, we searched Google Scholar and references of all articles for any additional studies. With the assistance of a professional librarian, we developed a systematic search strategy using appropriate keywords and MeSH terms and these are detailed in the data availability section (see Extended data).30 The systematic review software management system Covidence was used to store citations, remove duplication and aid screening.
Two review authors (AAA and MS) independently screened the titles and abstracts of all citations. The full texts of all potentially eligible studies were independently reviewed for inclusion confirmation. Any disagreement was resolved through discussion within the review team.
Data were independently extracted from included studies using a standardized data extraction form by two reviewers (AAA and MS). The information extracted included type and setting of the study, recruitment information, participant characteristics (age and underlying conditions), inclusion criteria, nature of interventions, in each group (e.g. flow rate and method of delivery), time-points of measurement and outcomes. Any disagreement was resolved through discussion with BB. Data that were unavailable or insufficient from publications were requested from study authors.
Two reviewers (AAA and MS) independently assessed the quality of included studies using the Cochrane risk of bias tool for RCTs and the Newcastle-Ottawa scale for cohort studies.31,32 Each potential source of bias was marked as high, low or unclear. We assessed the quality of the evidence associated with HFNT for AT2RF using GRADE to determine the strength of the evidence into one of four grades: high, moderate, low or very low.33 The quality of evidence is reported in the Summary of Findings (SOF) tables (Tables 1,2,3).
Patient or population: Acute hypercapnic respiratory failure patient Setting: Acute Care Intervention: HFNT Comparison: NIV | |||||
---|---|---|---|---|---|
Outcomes | Interventions | MD*/ OR* (95%)/p-value | № of participants analyzed (studies) | The certainty of the evidence (GRADE) | |
NIV* Median (IQR*) or mean (SD*) | HFNT* Median (IQR*) or mean (SD*) | ||||
Primary outcome a. PaCO2 (kPa*)34 time-point: 4 hours | 7.6 (6.3 – 9.3) | 6.7 (5.6 – 7.7) | P = 0.03 | 65 (1 RCT) | ⊕⊕⊕O Moderate2 |
b. PaCO2 (kPa*)36 time-point: 6 hours | 7.7 (1.6) | 8.5 (2) | MD 0.80 [0.00, 1.60] | 88 (1 RCT) | ⊕OOO Very Low2,4 |
c. PaCO2 (kPa*)23 time-point: 24 hours | 6.6 (1.9) | 6.3 (2.1) | MD −0.30 [−1.14, 0.54] | 88 (1 Cohort) | ⊕OOO Very Low 2,3 |
d. PaCO2 (kPa*)35 time-point: 5 days | 8 (1.9) | 7.8 (1.9) | MD −0.20 [−0.77, 0.37] | 165 (1 RCT) | ⊕⊕⊕O Moderate2 |
Secondary outcome (continuous data) a. PaO2 (kPa*)34 time-point: 4 hours | 11.7 (10.3 – 12.9) | 11.1 (5.3 – 13.2) | P = 0.71 | 65 (1 RCT) | ⊕⊕⊕O Moderate2 |
b. PaO2 (kPa*)36 time-point: 6 hours | ‡N/R | ‡N/R | ‡N/R | 88 (1 RCT) | ⊕OOO Very Low2,4 |
c. PaO2 (kPa*)23 time-point: 24 hours | 11.3 (3.1) | 11.2 (2.5) | MD −0.10 [−1.28, 1.08] | 88 (1 Cohort) | ⊕OOO Very Low2,3 |
d. PaO2 (kPa*)35 time-point: 5 days | ‡11 (2.1) | ‡10.9 (2) | ‡MD −0.10 [0.72, 0.52] | 165 (1 RCT) | ⊕⊕⊕O Moderate2 |
e. pH34 time-point: 4 hours | 7.35 (7.3-7.4) | 7.4 (7.3-7.4) | P = 0.24 | 65 (1 RCT) | ⊕⊕⊕O Moderate2 |
f. pH36 time-point: 6 hours | N/R‡ | N/R‡ | N/R‡ | 88 (1 RCT) | ⊕OOO Very Low2,4 |
g. pH23 time-point: 24 hours | 7.4 (0.1) | 7.4 (0.1) | MD 0.00 [−0.03, 0.03] | 88 (1 Cohort) | ⊕⊕OO Low3 |
h. pH35 time-point: 5 days | 7.4 (0.1)‡ | 7.35 (0.1)‡ | MD −0.05 [0.08, 0.01]‡ | 165 (1 RCT) | ⊕⊕⊕O Moderate2 |
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | |||||
Explanation 1- Downgraded for indirectness because of the study population 2- Downgraded for imprecision for a wide confidence interval, the small sample size 3- Downgraded for study design (non-RCT) 4- Downgraded for risk of bias |
Patient or population: Acute hypercapnic respiratory failure patient Setting: Acute Care Intervention: HFNT Comparison: NIV | ||||||
---|---|---|---|---|---|---|
Outcomes | Interventions | MD*/OR* (95%)/p-value | № of participants analyzed (studies) | The certainty of the evidence (GRADE) | Comments | |
NIV* n/N* | HFNT* n/N* | |||||
Secondary outcome (Dichotomous data) a. Mortality rate23 time-point: 30-day | 44/8 | 44/7 | OR 0.85 [0.28, 2.59] | 88 (1 Cohort) | ⊕⊕OO Low3 | |
b. Mortality rate36 time-point: in-hospital mortality | 39/6 | 40/2 | OR 0.29 [0.05, 1.53] | 80 (1RCT) | ⊕⊕⊕O Moderate2 | The study didn’t provide the time-point for mortality. |
c. Intubation rate36 time-points: 6 hours | 39/1 | 40/1 | OR 0.97 [0.06, 16.14] | 80 (1RCT) | ⊕⊕⊕O Moderate2 | |
d. Intubation rate34 time-point: 72 hours | 31/5 | 34/2 | OR 0.33 [0.06, 1.81] | 65 (1 RCT) | ⊕⊕⊕O Moderate2 | |
e. Intubation rate23 time-points: 30-day | 44/12 | 44/11 | OR 0.89 [0.34, 2.30] | 88 (1 Cohort) | ⊕⊕OO Low3 | |
f. Dysponea34,36 | - | - | - | 145 (2RCTs) | - | Dyspnoea was measured by 2 studies at various time points. It was assessed by modified Borg. |
g. Patient comfort35,36 | - | - | - | 245 (2 RCTs) | - | Comfort was measured by 2 studies at various time points. It was assessed by a self-designed survey and a 10-point numerical rating scale. |
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
Explanation 1- Downgraded for indirectness because of the study population 2- Downgraded for imprecision for a wide confidence interval, the small sample size 3- Downgraded for study design (non-RCT) 4- Downgraded for risk of bias |
Patient or population: Acute hypercapnic respiratory failure patient Setting: Acute Care Intervention: HFNT Comparison: LFO | ||||||
---|---|---|---|---|---|---|
Outcomes | Interventions | MD* (95%) | № of participants analysed (studies) | The certainty of the evidence (GRADE) | Comments | |
LFO* Mean (SD*) | HFNT* Mean (SD*) | |||||
Primary outcome a. PaCO2 (KPa*)24 time-point: 30 minutes | 6.5 (1.3) | 6.3 (1.3) | -0.20 [-1.24, 0.84] | 24 (1 RCT) | ⊕OOO Very low 2,4 | |
Secondary outcome (continuous) a. Patient comfort24 | - | - | - | 24 (1 RCT) | ⊕OOO Very Low2,4 | The questions used to assess patient comfort were not validated, and the sample size was low |
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
Explanation 1- Downgraded for serious indirectness because of the study population 2- Downgraded for serious imprecision for a wide confidence interval, the small sample size 3- Downgraded for study design (non-RCT) 4- Downgraded for risk of bias |
Measurement of effect
RevMan software (Review Manager, version 5.3) was used for data analysis. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs) for binary variables and mean differences (MD) with 95% CIs for continuous variables. A meta-analysis was planned, but there were insufficient studies and results are presented narratively.
Subgroup and sensitivity analysis
The planned subgroup analyses of patient conditions (COPD, neuromuscular disorders, and interstitial lung disease), and the planned sensitivity analysis excluding trials with a high risk of bias could not be undertaken due to the low number of trials.
The search identified 727 records. Following the removal of duplicates and non-eligible studies, 39 full-text studies were screened and 34 studies were excluded. Five studies with 425 participants were included in this review (Figure 1).23,24,34–36
The characteristics of the included studies are summarized in Table 4. Four studies were RCTs23,24,34–36 and one was a cohort study.23 Four studies compared HFNT with NIV23,34–36 and one RCT compared HFNT with LFO using simple nasal prongs.24 The disease state of interest was an acute-moderate hypercapnic respiratory failure (n = 88) in one study,23 and AECOPD (n = 337) in the remaining four studies.24,34–36
Author and year | No. of participants | Country | Setting | Study design | Population | Intervention (flow rate L/min) | Control | Outcomes measured relevant for this review |
---|---|---|---|---|---|---|---|---|
Cortegiani et al.36 2020 | 80 | Italy | Emergency Department, Intensive Care Units or Respiratory Unit | RCT* | AECOPD* | HFNT* (60 L/min) | NIV* | PaCO2, PaO2, pH, intubation rate, mortality, dyspnoea score, comfort, hospital stay |
Doshi et al.34 2020 | 65 | United States of America | Emergency department | RCT* | AECOPD* | HFNT* (35 L/min) | NIV* | PaCO2, PaO2, pH, dyspnoea score, intubation rate, hospital stay |
Cong et al.35 2019 | 168 | China | Intensive care unit | RCT* | AECOPD* | HFNT* (30 – 35 L/min) | NIV* | PaCO2, PaO2, pH, comfort, hospital stay |
Lee et al.23 2018 | 88 | South Korea | Emergency department | Cohort | Acute-moderate hypercapnic respiratory failure | HFNT* (35 L/min) | NIV* | PaCO2, PaO2, pH, intubation rate, mortality |
Pilcher et al.24 2017 | 24 | New Zealand | Emergency department | RCT* | AECOPD* | HFNT* (35 L/min) | Standard nasal prong | PaCO2, patient tolerability |
The risk of bias assessments for the four RCTs are described in Figure 2.24,34–36 Blinding of participants and personnel were not possible in the trials. One trial showed a high risk for selection bias due to unexplained randomization sequence and allocation concealment.35 The trials showed a high risk or unclear risk of detection bias due to no34,35 or unclear24 blinding of the outcomes assessor. One trial showed a high risk of attrition bias due to unreported incomplete data.34 The cohort study showed a low risk of bias in all domains and did not describe how the outcomes were assessed.23
Changes in PaCO2 after the intervention was reported in all five studies (Table 5),23,24,34–36 four studies compared HFNT to NIV.23,34–36 Doshi et al.34 reported no significant difference in PaCO2 at one hour between HFNT and NIV but there was a significant reduction in PaCO2 at four hours (HFNT 6.7, 5.6 – 7.7 vs NIV 7.6, 6.3 – 9.3 (Median, interquartile range (IQR)). In the other studies comparing HFNT to NIV,23,35,36 there was no significant difference in PaCO2 at various time-points with a similar trend in PaCO2 (Figure 3). Pilcher et al.24 compared HFNT with LFO at various five-minute time intervals with no significant difference, but when adjusted for the baseline PaCO2, they reported a significant improvement in PaCO2 by HFNT when compared to LFO.
Study | Time-points | HFNT* n/N* | HFNT* Mean (SD*) or Median (IQR*) | n/N* | Mean (SD*) or Median (IQR*) | Mean difference | ||
---|---|---|---|---|---|---|---|---|
NIV* | LFO* | NIV* | LFO* | |||||
Doshi et al.34 2020 | Baseline | 34/34 | 56 (26 – 112) | 34/31 | - | 64.6 (38 – 137) | - | - |
1 hour | 34/33 | 56 (23 – 130) | 34/31 | - | 63 (31 – 122) | - | - | |
4 hour | 34/27 | 50 (31 – 74) | 34/25 | - | 57 (35 – 113) | |||
Cortegiani et al.36 2020 | Baseline | 80/40 | 9.8 (1.7) | 80/39 | - | 9.6 (1.7) | - | 0.20 [−0.55, 0.95] |
2 hours | 80/40 | 9.1 (2.1) | 80/39 | - | 8.4 (1.8) | - | 0.70 [−0.16, 1.56] | |
6 hours | 80/40 | 8.5 (2) | 80/39 | - | 7.7 (1.6) | - | 0.80 [0.00, 1.60] | |
Cong et al.35 2019 | Baseline | 168/84 | 9.6 (2.2) | 168/84 | - | 9.6 (2.3) | - | 0.00 [−0.68, 0.68] |
12 hours | 168/84 | 8.4 (2.1) | 168/84 | - | 8.4 (2.1) | - | 0.00 [−0.64, 0.64] | |
5 days | 168/84 | 7.8 (1.9) | 168/84 | - | 8 (1.9) | - | −0.20 [−0.77, 0.37] | |
Lee et al.23 2018 | Baseline | 88/44 | 7.50 (1.3) | 88/44 | - | 7 (1.2) | - | 0.50 [−0.02, 1.02] |
6 hours | 88/44 | 6.20 (2.2) | 88/44 | - | 6.90 (2.3) | - | −0.70 [−1.64, 0.24] | |
24 hours | 88/44 | 6.30 (2.1) | 88/44 | - | 6.6 (1.9) | - | −0.30 [−1.14, 0.54] | |
Pilcher et al.24 2017 | Baseline | 24/12 | 6.50 (1.3) | - | 24/12 | - | 6.50 (1.3) | 0.00 [−1.04, 1.04] |
5 minutes | 24/12 | 6.40 (1.3) | - | 24/12 | - | 6.50 (1.3) | −0.10 [−1.14, 0.94] | |
10 minutes | 24/12 | 6.30 (1.3) | - | 24/12 | - | 6.50 (1.3) | −0.20 [−1.24, 0.84] | |
15 minutes | 24/12 | 6.30 (1.3) | - | 24/12 | - | 6.50 (1.3) | −0.20 [−1.24, 0.84] | |
20 minutes | 24/12 | 6.35 (1.3) | - | 24/12 | - | 6.40 (1.3) | −0.05 [−1.09, 0.99] | |
25 minutes | 24/12 | 6.40 (1.3) | - | 24/12 | - | 6.40 (1.3) | 0.00 [−1.04, 1.04] | |
30 minutes | 24/12 | 6.30 (1.3) | - | 24/12 | - | 6.50 (1.3) | −0.20 [−1.24, 0.84] |
pH level was reported in three studies.23,34,35 Doshi et al.34 reported no significant difference in pH between HFNT and NIV at one hour (HFNT 7.36, 7.34-7.42 vs NIV 7.31, 7.27-7.37, (Median, IQR)) or four hours (HFNT 7.38, 7.34-7.42 vs NIV 7.35, 7.33-7.37, (Median, IQR)). Cong et al.35 reported no significant difference in pH between HFNT and NIV at 12 hours (MD -0.10, 95% CI -0.13, 0.06) or five days (MD -0.05, 95% CI -0.08, -0.01). Lee et al.23 showed no significant difference in pH between HFNT and NIV at six hours (MD 0.02, 95% CI -0.16, 0.20) or 24 hours (MD 0.00, 95% CI -0.03, 0.03). The PaO2 level was reported in four trials.23,34–36 Doshi et al.34 reported no significant difference in PaO2 between HFNT and NIV at one hour (HFNT 13.2, 10.7-19.2 vs NIV 15.1, 8.8-22.9, (Median, IQR)) or four hours (HFNT 11.1, 5.3-13.2 vs NIV 11.7, 10.3-12.9, (Median, IQR)). Cong et al.35 reported no significant difference in PaO2 between HFNT and NIV at 12 hours (MD 0.00 kPa, 95% CI −0.70, 0.70) or five days (MD −0.10 kPa, 95% CI −0.72, 0.52). Lee et al.23 reported no significant difference in PaO2 between HFNT and NIV at six hours (MD 0.00 kPa, 95% CI −1.30, 1.30) or 24 hours (MD −0.10 kPa, 95% CI −1.28, 1.08).
Patient comfort was reported in three RCTs.24,35,36 Patient comfort assessed using a self-designed survey in Cong et al.35 a 10-point numerical rating scale in Cortegiani et al.36 and the Likert scale in Pilcher et al.24 showed that HFNT was more comfortable than LFO but louder than LFO (Table 6).
Study | Time-points | Question | HFNT‡ n/N‡ | Mean (SD‡) HFNT‡ | SNP‡ N/n‡ | Mean (SD‡) SNP‡ | MD‡ |
---|---|---|---|---|---|---|---|
Pilcher et al.24 2017 | 30 minutes | I found wearing the nasal interface: 1 = Very comfortable 5 = Very uncomfortable | 24/12 | 2.4 (1.3) | 24/12 | 2.4 (1.1) | 0.00 [−0.96, 0.96] |
The nasal interface was: 1 = Light 5 = Heavy | 24/12 | 2.2 (1.2) | 24/12 | 1.9 (1.2) | 0.30 [−0.66, 1.26] | ||
The intervention was: 1 = Quiet 5 = Noisy | 24/12 | 2.6 (1.4) | 24/12 | 1.3 (0.6) | 1.30 [0.44, 2.16] | ||
My nasal passages were: 1 = Comfortable 5 = Dry | 24/12 | 1.9 (1.2) | 24/12 | 3.0 (1.7) | −1.10 [−2.28, 0.08] | ||
Breathing through my nose was: 1 = Easy 5 = Very difficult | 24/12 | 2.3 (1.2) | 24/12 | 1.8 (1.0) | 0.50 [−0.38, 1.38] |
The intubation rate was reported in three studies comparing HFNT with NIV.23,34,36 Doshi et al.34 demonstrated no significant difference in intubation rate at 72 hours (RCT; OR 0.33 95% CI 0.06, 1.81). Cortegiani et al.36 reported no significant difference in intubation rate at two hours (RCT; OR 0.32 95% CI 0.01, 8.02) or six hours (RCT; OR 0.97 95% CI 0.06, 16.14). Lee et al.23 reported no significant difference at 30 days (cohort; OR 0.89 95% CI 0.34, 2.30) (Table 7).
Study | Time-points | HFNT‡ | NIV‡ | P-value | ||||
---|---|---|---|---|---|---|---|---|
n/N‡ | Median | IQR‡ | n/N‡ | Median | IQR‡ | |||
Cortegiani et al.36 2020 | 2 hours | 80/40 | 1 | [0–2] | 80/39 | 3 | [1–5] | 0.0010 |
6 hours | 80/40 | 0 | [0–2] | 80/39 | 2 | [1–4] | 0.0003 |
The mortality rate was reported in two studies23,36 and there was no difference between HFNT and NIV groups (Table 7).
The dyspnoea score, measured by Modified Borg score, a self-reported rating of perceived dyspnoea on a scale of one to 10, with 10 being the worst, was reported in two trials.34,36 The reduction in the dyspnoea score was similar between HFNT and NIV at different time points in both trials (Table 8).
Study | Time-points | Treatment | n/N‡ | Comfort N (%) |
---|---|---|---|---|
Cong et al.35 2019 | 12 hours and 5 days | NIV‡ | 168/84 | 57 (67.9) |
HFNT‡ | 168/84 | 75 (88.2) | ||
P-value | 0.008 |
Length of stay in hospital was reported by three trials34–36 comparing HFNT and NIV with no difference between the two groups (Table 9).
Study | Outcome | Time-points | HFNT* n/N* | NIV* n/N* | OR* (95%) |
---|---|---|---|---|---|
Lee et al.23 2018 | Mortality rate | 30-day | 44/7 | 44/8 | 0.85 [0.28, 2.59] |
Cortegiani et al.36 2020 | Mortality rate | In hospital mortality | 40/2 | 39/6 | 0.29 [0.05, 1.53] |
Doshi et al.34 2020 | Intubation rate | 72-hours | 34/2 | 31/5 | 0.33 [0.06, 1.81] |
Cortegiani et al.36 2020 | Intubation rate | 2 hours | 40/0 | 39/1 | 0.32 [0.01, 8.02] |
6 hours | 40/1 | 39/1 | 0.97 [0.06, 16.14] | ||
Lee et al.23 2018 | Intubation rate | 30-days | 44/11 | 44/12 | 0.89 [0.34, 2.30] |
Study | Time points | HFNT‡ | NIV‡ | P-value/MD‡ | ||
---|---|---|---|---|---|---|
n/N‡ | Median (IQR‡) /Mean (SD‡) | n/N‡ | Median (IQR‡)/Mean (SD‡) | |||
Doshi et al.34 2020 | 30 minute | 65/33 | 4 (3-7) | 65/29 | 4 (2-6) | 451 |
1 hour | 65/31 | 3 (2-6) | 65/29 | 3 (1.5-5) | 0.595 | |
90 minute | 65/31 | 3 (2-5) | 65/29 | 2 (0-4.5) | 0.11 | |
4 hours | 65/28 | 2 (1-3.75) | 65/24 | 3 (1-4) | 0.788 | |
Cortegiani et al.36 2020 | 2 hours | 80/40 | 3 (2) | 80/39 | 3 (2) | 0.00 [−0.88, 0.88] |
6 hours | 80/40 | 5 (2) | 80/39 | 5 (2) | 0.00 [−0.88, 0.88] |
Within the AT2RF patient population where HFNT is used as the initial management strategy, this systematic review has identified very few studies: four comparing HFNT with NIV and one comparing HFNT with LFO. HFNT, compared with NIV, showed a significant difference in PaCO2 after four hours of treatment,34 although the difference was not demonstrated at 24 hours,23 five days,35 six hours36 and a similar lack of difference is seen when compared to LFO at 30 minutes.24 The reduction in PaCO2 between the two groups at four hours demonstrated in Doshi et al.34 is not adjusted for the baseline difference in PaCO2 between the two groups. The absolute reduction of PaCO2, when compared to the baseline, was 0.8 kPa for the HFNT group and 0.99 kPa in the NIV group, which suggest that the significant difference was secondary to baseline difference rather than true clinical superiority. Compared with NIV or LFO, HFNT showed no difference in pH and PaO2 and has similar intubation rates, mortality and hospital length of stay. HFNT, when compared to NIV, is associated with better comfort as presented by Cong et al.35 and Cortegiani et al.,36 although this was not replicated in Pilcher et al.24 This systematic review found that despite the potential benefit of improved patient comfort and increasing use of HFNT in the treatment of AT2RF, the current evidence is quite poor. The certainty of the evidence was primarily impacted by the small number of trials and sample sizes, selection bias and few RCTs. Lack of blinding is a potential source of bias but the nature of the intervention precludes blinding, while the objective nature of the outcome measures reduces the risk of bias. Hence, objective outcome measures were not downgraded for lack of blinding while subjective measures such as comfort score and dyspnoea score were downgraded.
In AT2RF, the production of CO2 is increased due to additional work of breathing, increased metabolism and failure to clear CO2. NIV failure occurs in a quarter of these patients needing further IMV. The extent of reduction in pH, associated with the elevated CO2, is significantly associated with NIV failure.37 Any medical optimization introduced early after the detection of AT2RF should be aimed at improving CO2 clearance and pH because the development of respiratory acidaemia post-admission is associated with a mortality of 33%.3 While current evidence has convincingly established the benefits of NIV for AT2RF, evidence for newer and better-tolerated technologies to reduce hypercapnia is urgently required due to the high intolerance rate leading to a late failure.10
In this systematic review focused on early intervention for AT2RF patients, there is no difference in various respiratory parameters between HFNT and NIV except for one study showing an improvement in PaCO2 at a single time-point. HFNT is associated with a reduction in PaCO2 and an increase in pH similar to NIV. While this could suggest that HFNT is non-inferior to NIV, HFNT cannot be recommended as an alternative management strategy to reduce PaCO2 due to the low quality of evidence, lack of standardization of time-points for PaCO2 measurement and the lack of adequately powered sample sizes. Similarly, in patients failing NIV due to compliance issues, HFNT may be a promising option to limit mechanical ventilation. This recommendation falls beyond the scope of this systematic review and is a clinical scenario that requires urgent attention. A similar response in CO2 to HFNT is reported in COPD patients with stable type 2 respiratory failure,38 post-acute NIV,39 post NIV failure,40–42 post-extubation43 and during breaks in NIV.21
Studies have shown a reduction in intubation rate and mortality between NIV versus usual care39 and a reduction in the length of hospital stay, lower incidence of complications with a longer-term benefit of fewer readmissions to hospital in the following year between NIV and IMV44 with one study suggesting a mortality benefit.45 HFNT, if equivalent to NIV, should ultimately reduce important outcomes such as intubation, mortality and health resource use. Three studies found no difference in intubation rate23,34,36 and three studies found no difference in length of stay34–36 thus suggesting therapeutic equivalence but the studies were not powered for these outcomes. Doshi et al.,34 showed that HFNT when compared to NIV had a similar therapy failure rate of approximately 25%. Patients receiving HFNT had a trend towards a shorter ICU stay, likely driven by a lower intubation rate in the HFNT group (5.9%) when compared to the NIV group (16.1%), which did not achieve statistical significance in this study that was not powered for this outcome.
A key balancing outcome is an increase in adverse outcomes that have been highlighted in studies comparing NIV to usual care that include a delay in escalation to IMV,46 increased mortality when compared to immediate IMV, and increased mortality when IMV is delayed.47 In this systematic review, Lee et al.23 and Cortegiani et al.36 taken together with lower intubation rate in the HFNT arm,34 suggests that HFNT is unlikely to be associated with harm through delayed initiation of IMV, but this hypothesis needs to be confirmed in a clinical trial.
One of the putative benefits of HFNT is patient comfort due to the lack of a tight-fitting mask, prevention of skin breakdown, better communication and mucous clearance.24 HFNT, when compared to NIV, was shown to be associated with improved comfort in Cong et al.35 and Cortegiani et al.36 In this review, Doshi et al.34 and Cortegiani et al.36 did not detect any difference in dyspnoea between HFNT and NIV. The lack of demonstrable benefit is likely secondary to the earlier time points in the studies investigating the role of HFNT in the initial management of AT2RF.
HFNT is increasingly emerging as a therapeutic option for AT2RF, but various studies have combined it with other clinical scenarios such as post-extubation,42 NIV interruption,21 or physiological studies24 and even in studies that explored its efficacy in acute exacerbations, the place of intervention could lead to bias, for example after initial management in the emergency medicine department, thus introducing unintentional bias such as lead-time bias as well selection bias.35 The location of patients in a closely monitored environment, as opposed to a general ward,47 might mask any adverse outcomes due to deterioration through earlier intervention. Hence, it is essential to investigate its utility in the early management of AT2RF in the emergency medicine department.
High flow nasal cannula can flush anatomical dead space, provide mild positive distending pressure, improve mucociliary clearance as well as be better tolerated.48 Depending on the type of respiratory failure, type 1 or 2, a specific nasal cannula design that alters flow pattern could have a differential effect. A small-bore nasal cannula as seen in high flow nasal insufflation might purge the anatomical dead space more efficiently, thereby providing minimal ventilator assistance.48,49
The strength of the systematic review is that it was conducted to a high standard following recommended methods for the conduct, quality assessment and reporting,50 using a comprehensive search strategy of all electronic databases. Despite this, the recommendations of the review are limited by the small number of trials, which highlights the need for further adequately powered trials.
We recommend that future research needs to address the following research gaps in the evidence base for the use of HFNT in AT2RF. Future trial designs should be randomized controlled trials, they should include sufficiently large patient numbers to ensure they are adequately powered for important clinical outcomes. Outcomes should be standardized with clear definitions including clinical outcomes, use validated scales and relevant time points.51 The role of nasal cannula diameter in the efficiency of CO2 clearance should be tested to determine whether the type of device used has an impact on therapy efficacy.52 Studies should also encompass a robust health economic analysis, include outcome analysis of patients who fail therapy and identify any features to predict the outcome of the therapy to allow patient selection.
In conclusion, this review found very few studies investigating the clinical efficacy of HFNT in AT2RF. A similar reduction in PaCO2 was seen between HFNT and NIV at various time-points,35,36 while a significantly higher PaCO2 clearance with HFNT, when compared to NIV, was demonstrated at an early time point in one study.34 Similarly, HFNT use was associated with better comfort in two studies,35,36 while a similar benefit was not shown in the other study.24 The evidence is also moderate in quality and the benefit demonstrated is limited to clinically irrelevant time points, with no studies powered to detect clinical outcomes. Therefore, a change in practice cannot be recommended until further high-quality clinical trials are conducted.
All data underlying the results are available as part of the article and no additional source data are required.
Queen’s University Belfast institutional data repository (Pure system): High flow nasal therapy for acute type 2 respiratory failure: A systematic review. https://doi.org/10.17034/4080c4eb-38f0-4c02-91ee-37129ceb65a6.30
This project contains the following extended data:
- Search strategy for Medline for research article High flow nasal therapy for acute type two respiratory failure. A systematic review.pdf
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Queen’s University Belfast institutional data repository (Pure system): PRISMA checklist for “High flow nasal therapy for acute type 2 respiratory failure: A systematic review”. https://doi.org/10.17034/4080c4eb-38f0-4c02-91ee-37129ceb65a6.30
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
The authors acknowledge support from the Deanship of Scientific Research at King Saud University and Queen’s University Belfast librarian, Richard Fallis, for his support in developing the search strategy.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
References
1. Sklar MC, Mohammed A, Orchanian-Cheff A, Del Sorbo L, et al.: The Impact of High-Flow Nasal Oxygen in the Immunocompromised Critically Ill: A Systematic Review and Meta-Analysis.Respir Care. 2018; 63 (12): 1555-1566 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Respiratory failure, HFNC, NIV, invasive mechanical ventilation
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Acute respiratory support
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 20 Sep 21 |
read | |
Version 1 16 Jun 21 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)